However, it is noteworthy that the tumor types varied considerably in these two populations, with nine of the 13 patients of GIS ≥33 in the exploratory biomarker analysis having tumor types known to be sensitive to PARP inhibitor (i.e., ovarian cancer, prostate cancer, or breast cancer). This evidence concerns the gene PARP1 and prostate carcinoma.